0,1,2
,,r the
three and nine months ended September 30 2023, respectively recognized primarily in cost of revenues,
and R&D expenses. For additional information see Note 1 of the Notes to Consolidated Financial,,
Statements included in Item 1 of this Quarterly Report on Form 10-Q.,,
